ORIGINAL ARTICLE

ASIAN JOURNAL OF MEDICAL SCIENCES

Elevated liver enzymes and its association with uncontrolled type 2 diabetes mellitus: A study from South India



Avinash HR¹, Naveen K Nandeppagoudar², Mamatha TR³, Arpith AG⁴

¹Assistant Professor, Department of General Medicine, Shri Atal Bihari Vajpayee Medical College and Research Institution, ²Postgraduate Resident, Department of General Medicine, Bangalore Medical College and Research Institute, ³Associate Professor, ⁴House Surgeon, Department of General Medicine, ESI-PGIMSR, Medical College and Hospital, Bengaluru, Karnataka, India

Submission: 27-12-2024

Revision: 30-01-2025

Publication: 01-03-2025

ABSTRACT

Background: Diabetes mellitus is one of the most common chronic diseases has been related to various liver illnesses such as liver enzyme derangements, nonalcoholic fatty liver disease, hepatocellular carcinoma, and cirrhosis. There has been increased interest on the contribution of liver enzymes to prediction of diabetes and glycemic control. Aims and Objectives: The aim is study was to correlate liver enzymes with Hemoglobin A1c (HbA1C) in type 2 diabetes mellitus (T2DM) with uncontrolled sugars. Materials and Methods: Diabetic patients seen on Outpatient Department basis or admitted as inpatients are included in this study. Information is collected and detailed history is taken using pre-formed proforma at the time of admission. Liver function tests are measured to all participants, and HbA1C value is measured. Liver enzymes are correlated with HbA1C values. Results: Among 119 patients, the mean age was 56.65 years. Eighty-three patients (69.7%) were males and 36 (30.3%) were females. The mean duration of diabetes is 8.84 ± 5.81 , mean HbA1c is 8.89 ± 2.62. Mean fasting blood sugar and post-prandial blood sugar were 179.4 ± 96.3 and 252 ± 136.5 , respectively. There is negative correlation is seen among Aspartate transferase (AST), gamma-glutamyl transferase (GGT) and AST/Platelet (PLT) ratio, but not alanine aminotransferase (ALT). However, there is negative Pearson correlation between HbA1C and liver enzymes as mentioned above which are statistically not significant except AST/PLT ratio. Conclusion: The importance of monitoring the liver function tests in uncontrolled T2DM patients was studied, which showed association among AST, GGT, and AST: ALT ratio with HbA1C. All were negatively correlated with HbA1C, but statistically significant correlation is seen only with AST: PLT ratio.

Key words: Uncontrolled sugars; Type 2 diabetes mellitus; Liver enzymes; Hemoglobin A1c; aspartate transferase: Platelet ratio

INTRODUCTION

Diabetes mellitus is a group of metabolic disorder that shares phenotype hyperglycemia. Diabetes mellitus is one of the most common chronic diseases causing morbidity and mortality.^{1,2} The IDF provides the latest figures, information and projections on diabetes worldwide. In 2021, approximately 537 million adults (20–79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.3 in 4 adults with diabetes live in low- and middle-income countries. Almost 1 in 2 (240 million) adults living with diabetes are undiagnosed.^{3,4} Diabetes has been related to various liver illnesses such as non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, and cirrhosis.⁵⁻⁷

Dr. Avinash HR, Assistant Professor, Department of General Medicine, Shri Atal Bihari Vajpayee Medical College and Research Institution, Bengaluru, Karnataka, India. **Mobile:** +91-9945335560. **E-mail:** avinashhr19@gmail.com

Access this article online

Website:

https://ajmsjournal.info/index.php/AJMS/index

DOI: 10.71152/ajms.v16i3.4382

E-ISSN: 2091-0576 P-ISSN: 2467-9100

Copyright (c) 2025 Asian Journal of Medical Sciences



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Address for Correspondence:

The liver has an important role in the maintenance of glucose homeostasis.⁸ Serum liver enzymes indicate the liver injury, these include gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), Alkaline phosphatase (ALP), and alanine aminotransferase (ALT), these are also measures for NAFLD which has been associated with insulin resistance⁹ and the risk of diabetes mellitus. In NAFLD, the altered liver enzyme levels which are biological markers linking liver disease and diabetes.^{10,11}

As recommended by ADA 2023 adults with type 2 diabetes or prediabetes, particularly those with obesity should be screened/risk stratified for NAFLD with clinically significant fibrosis (moderate fibrosis to cirrhosis) using a calculated fibrosis-4 index (derived from age, ALT, AST, and platelets [PLTs]). Clinicians underestimate its prevalence and do not consistently implement appropriate screening strategies, thus missing the diagnosis of the potentially progressive form of NAFLD in high-risk groups, such as those having obesity or type 2 diabetes mellitus (T2DM). The under diagnosis is compounded by sparse referral and inadequate prescription of medications with proven efficacy in NASH.^{12,13}

There has been increased interest on the contribution of liver enzymes to prediction of diabetes. In this regard, although many studies have shown a relation between diabetes and elevated liver enzymes, the results remain inconsistent and less studies on this topic.¹⁴

Many studies have showed a significant relationship between high levels of serum liver enzymes including AST, ALT, GGT, and diabetes mellitus.^{14,15} Even a significant increase was observed for GGT, ALT and ALP levels but not AST in some studies.¹¹ Some studies showed that significant increases in ALT and AST are associated with diabetes mellitus.¹⁶⁻¹⁸ On the other hand, in some studies, only an increase in GGT was associated with diabetes mellitus.¹⁸

Aims and objectives

The aim is study the correlation of the level of liver enzymes with Hemoglobin A1c (HbA1C) level in patients with T2DM.

MATERIALS AND METHODS

Sample size

In a study done by Mojgan et al.,³¹ 11.4% of diabetic patients had elevated ALT levels with 5% absolute precision, sample required for the study is 100.

 $n=4pq/d^2=100$ Sample size taken in the study is 119.

Inclusion criteria

- Patients willing to give written informed consent
- Patients with T2DM.

Exclusion criteria

- Age <18 years
- Active or chronic inflammation
- Autoimmune diseases
- Malignancy
- Acute or chronic renal/hepatic diseases or coronary artery disease
- Type 1 diabetes
- Alcohol consumption ≥ 20 g/day in the past 3 month
- Previous diagnosis of acute or chronic liver disease
- Intake of hepatotoxic drugs
- Inflammatory diseases.

Statistical analysis

Statistical Package for the Social Sciences (SPSS) version 20 (IBM SPASS statistics [IBM corp. released 2011] was used to perform the statistical analysis

- Data were entered in the excel spread sheet
- Descriptive statistics of the explanatory and outcome variables were calculated by mean, standard deviation for quantitative variables, frequency, and proportions for qualitative variables.

Methodology

Diabetic patients seen on Outpatient Department basis or admitted as inpatients are included in this study. Information is collected and detailed history is taken using pre-formed proforma at the time of admission. The diagnosis of T2DM was made according to the American Diabetes Association guidelines. Liver function tests are measured to all participants, and HbA1C value is measured. Liver enzymes are correlated with HbA1C values.

RESULTS

Figure 1 shows among 119 patients in the study, the mean age is 56.65. Maximum age of >75 years and minimum of age 35 years is considered. In our study, the age group distribution has 50 patients in middle age group (46–55 years), followed by 30 members in age group of 56–65 years, 24 patients in the age group of 66–75 years and 13 are in the age group of 35–45 years and 2 are elderly >75 years, respectively. In the study, 83 patients (69.7%) are male and 36(30.3%) are females.

In our study, there were many factors which were statistically significant, which include AST, GGT, and triglycerides with P<0.05.AST and GGT values were statistically significant but not ALT in liver enzymes. However there was association between triglycerides and HbA1C seen. Apart



Figure 1: Demographic profile: Age and sex Avinash HR¹, Naveen K Nandeppagoudar², Mamatha TR³, Arpith AG⁴

from that AST/PLT ratio is also statistically significant which was seen in our study.

The above table shows the correlation between diabetic profile and liver enzymes. There is negative correlation is seen among AST, GGT, and AST/PLT ratio, but not ALT. However, there is negative Pearson's correlation between HbA1C and liver enzymes as mentioned above which are statistically not significant except AST/PLT ratio.

DISCUSSION

The present study has been undertaken to throw some light on derangement of liver enzymes in patients with uncontrolled type 2 diabetic patients.

In our study among 119 patients, the mean age is 56.65. Maximum age of >75 years and minimum of age 35 years. The age group distribution has 50 patients in middle age group (46–55 years), followed by 30 members in age group of 56–65 years, 24 patients in the age group of 66–75 years and 13, 2 in 35–45 years, and >5 years, respectively (Table 1). In a study done by Alam et al., the mean age of T2DM subjects was 46.4±13.6 years and 39.2±12.0 years for healthy control. The age of the diabetic subjects ranges from 27–87 years with a mean of 56.91 ± 11.00 years with the mean of 53.38 ± 13.28 in a study done in Nepal by Jha et al. Similarly, the mean ages of the T2DM and controls participants were 55.76 ± 10.11 and 50.93 ± 5.41 ,¹⁷ respectively, in a study done in Ethopia by Shibabaw et al.

There were 83 patients (69.7%) were male and 36 (30.3%) were female in our study (Table 3). Men constituted 121 (63%) of T2DM participants and 116 (60.4%) of the controls in a study in Ethopia by Shibabaw et al. Similarly, 68 (68%) male and 32 (32%) female in a study done by Omer.

In many studies, the authors used elevated AST enzyme as marker for in diabetes risk assessment.²¹ In another recently published comparative cross-sectional study, it

44

Table 1: Basic characteristics				
Variables	Values			
Sample size	119			
Age, mean (SD)	56.65 (9.67)			
Gender	Female-36,			
	Male-83			
Duration of diabetes (years), mean (SD)	8.84 (5.81)			
HbA1C, mean (SD)	8.89 (2.65)			
FBS, mean (SD)	179.44 (96.35)			
PPBS, mean (SD)	252.07 (136.59)			
n our study, mean duration of diabetes is 8.84±5.81, mean HbA1C is 8.89±2.62.				

Mean FBS and PPBS were 179.4±96.3 and 252±136.5 respectively. HbA1C: Hemoglobin A1c, FBS: Fasting blood sugar, PPBS: Post-prandial blood sugar

was found that there is prevalence of abnormal LFTs in T2DM compared to healthy persons.²² The other possible assumption is the susceptibility to inflammation of the liver which alters the function of the liver and induces a change in liver biomarkers.^{23,24}

In our study, mean duration of diabetes is 8.84 ± 5.81 , mean HbA1C is 8.89 ± 2.62 . Mean FBS and PPBS were 179.4 \pm 96.3 and 252 \pm 136.5 respectively. The mean fasting Glucose (mg/dL) 201.26 \pm 24.62 HbA1C (%) 8.1 ± 0.33 in a study done by Alam et al. Mean FBS was (mg/dL) 189.80 \pm 64.45 in a study done by Shibabaw et al.

In our study, there were many factors which were statistically significant, which include AST, GGT and triglycerides with P<0.05. FBS in patients with HbA1C <7 142.77, >7 193.51 and PPBS with HBA1C <7 179.36 and 279.98 which is statistically significant. Furthermore, total cholesterol and triglycerides as a part of work up of T2DM done also showed significant statistical association (Table 2).

Indian studies show high prevalence of deranged LFTs of about 71.2% and 70%, respectively in individuals with T2DM.²⁴ Some studies also showed abnormal liver parameters with a relatively lower rate of 53%. Hence, the frequency of deranged LFTs reported, in the case of Indian diabetes, is around 50–70%.²⁵⁻²⁸

In a study done by Alam et al., all liver enzymes showed a negative correlation with the HbA1C. ALT and AST also showed a negative correlation with the fasting blood glucose except for ALP had a positive correlation with the FBG similar to our study.

In a study done by Ying Wan and Li-Zhen Yang (2022), there was association between blood glucose (FPG, PBG, and HbA1C) and elevated GGT and AKP, which suggests that GGT and AKP may be new indicators of whether the control of FPG, PBG, and HbA1C in T2DM patients is effective.²⁹

A study done by Omer has revealed that elevated HbA1C and triglyceride in T2DM with high GOT and GPT is

ParametersHBA1CManStandard deviationP-valueAge755.6111.060.46eDuration of DM (Years)577.7250.090.14Age of onset of diabetes5747.739.850.00Age of onset of diabetes5747.739.850.00FBS (mydL)57142.7783.960.00PPS (mydL)57179.36144.400.00PPS (mydL)57179.36137.690.00PBS (mydL)5712.132.630.00PBS (mydL)5712.132.630.00PBS (mydL)5712.132.630.00PBS (mydL)5712.132.630.00PBS (mydL)5712.132.630.00PD (mydL)572.743.031.900.077PD (mydL)572.451.100.224PD (mydL)572.451.100.224TC77.464.822.816.110.071Patelet count572.451.000.047PD (mydL)57149.9050.470.015Triglycerides5712.342.892.410.014PD (mydL)57149.9050.470.015Triglycerides571.02.843.031.900.014PD (mydL)573.5514.720.015Triglycerides570.911.48.830.032TB770.840.94 <th colspan="7">Table 2: Distribution and correlation of diabetic profile and HbA1C</th>	Table 2: Distribution and correlation of diabetic profile and HbA1C						
Age 7 55 61 11.06 0.468 Duration of DM (Years) 57 7.72 5.09 0.194 Age of onset of diabetes 57 9.27 6.05 0.950 FBs (mg/dL) 57 47.717 9.85 0.010 PPBS (mg/dL) 57 179.351 97.52 0.000 FB (g%) 57 12.13 2.63 0.440 NCV 7 85.61 1.10 0.077 FB (g%) 57 12.13 2.63 0.010 7 85.61.22 303.100 0.077 FLC 7 7.44.64.2 2.816.11 0.024 7 2.45 1.10 0.224 0.040 7 2.75 1.22 0.010 0.077 Platelet count 57 2.45 1.10 0.244 9 7 7.75 1.22 0.016 7 2.75 1.22 0.016 0.017 10 cholesterol 57	Parameters	HBA1C	Mean	Standard deviation	P-value		
-7 67.06 9.13 Duration of DM (Years) -7 7.72 5.09 0.194 Age of onset of diabetes -7 47.77 9.36 0.010 Age of onset of diabetes -7 47.77 83.96 0.010 FBS (mg/dL) -7 193.51 97.62 0.010 PPBS (mg/dL) -7 121.33 2.63 0.010 HB (g%) -7 12.13 2.63 0.010 MCV -7 84.64 5.85 0.000 TLC -7 7464.82 281.01 0.070 Platel count -7 2.45 1.10 0.224 Total cholesterol -7 7.464.82 280.41 0.015 Tiglycerides -7 7.475 1.22 0.024 Total cholesterol -7 7.464.82 280.44 0.045 Tiglycerides -7 17.76.1 56.65 0.015 Tiglycerides -7 0.716 14.83 0.591	Age	7	55.61	11.06	0.466		
Duration of DM (Years) 57 7.72 5.09 0.194 Age of onset of diabetes 57 47.78 9.85 0.950 FBS (mg/dL) 57 142.77 83.36 0.010 PPBS (mg/dL) 57 173.36 104.40 0.000 HB (g%) 57 173.36 104.40 0.000 HB (g%) 57 12.13 2.63 0.010 CV 7 82.64 5.85 0.040 CV 7 82.64 5.85 0.040 CLC 7 7464.82 2816.1 0.077 CLC 7 7464.82 2816.1 0.071 Tigly cerides 57 140.90 5.47 0.015 Tigly cerides 57 140.90 5.65 0.014 Tigly cerides 57 177.61 56.65 0.015 Tigly cerides 57 0.91 1.66 0.014 Tigly cerides 57 0.83 1.91 0.84		>7	57.06	9.13			
>7 9.27 6.05 Age of onset of diabetes >7 47.91 10.63 0.950 FBS (mg/dL) >7 142.77 83.96 0.010 >7 193.51 97.52 0000 >7 279.98 137.69 0.014.40 0.000 >7 279.98 137.69 0.040 0.071 >7 12.13 2.63 0.040 0.077 MCV 7 82.14 5.99 0.040 Platelet count 57 2.45 1.10 0.224 TLC 7 7464.82 2.816.11 0.077 Table count 57 2.45 1.10 0.224 Total cholesterol 57 149.90 50.47 0.015 Triglycenides 57 177.61 56.65 0.044 HDL cholesterol-direct 57 37.19 14.83 0.591 TB 7 0.91 1.66 0.044 Abumin 57 3.29	Duration of DM (Years)	≤7	7.72	5.09	0.194		
Age or nest of diabetes 57 47, 78 9.85 FBS (mg/dL) 57 142,77 8.86 0.010 PFBS (mg/dL) 57 179,36 104,40 0.000 PFBS (mg/dL) 57 179,36 104,40 0.000 HB (g%) 57 11,34 2,43 0.135 MCV 7 82,14 5.99 0.040 NCV 7 84,64 5.85 0.077 CLC 7 74,45 1.10 0.224 NCV 7 84,54 2,816 0.077 CLC 7 744,822 2816,11 0.072 TC 7 2,45 1.10 0.224 Total cholesterol 57 122 0.015 Triglycerides 57 110,48 49.96 0.041 HDL cholesterol-direct 57 37,19 14.83 0.91 TB 7 0.91 1.66 0.94 0.93 Tpotein 57 <td></td> <td>>7</td> <td>9.27</td> <td>6.05</td> <td></td>		>7	9.27	6.05			
FBS (mg/dL) 57 447.78 9.85 FBS (mg/dL) 57 149.51 97.52 PPBS (mg/dL) 57 179.98 137.69 B (g%) 57 127.9.98 137.69 HB (g%) 57 121.3 2.63 MCV 7 82.14 5.99 0.000 F7 7464.82 2816.11 0.77 Platelet count 57 2.45 1.10 0.224 Total cholesterol 57 149.90 50.47 0.015 Triglycerides 57 170.48 49.96 0.044 The cholesterol-direct 57 213.84 289.24 0.015 Triglycerides 57 170.48 49.96 0.044 The cholesterol-direct 57 37.19 14.83 0.511 Triglycerides 57 0.91 1.66 0.908 Triglycerides 57 0.91 1.68 0.91 Triglycerides 57 0.83 1.91	Age of onset of diabetes	≤7	47.91	10.63	0.950		
FBS (mg/dL) 57 142.77 83.96 0.010 97 193.51 97.52 PPBS (mg/dL) 57 179.36 104.40 0.000 57 279.98 137.69 0.010 HB (g%) 57 11.34 2.43 0.135 57 12.13 2.63 0.000 77 82.14 5.99 0.040 70 7 84.64 5.85 71 7.64.62 2816.11 0.077 71 7.64.62 2816.11 0.071 71 7.65 1.22 0.031.90 Platelet count 57 2.75 1.22 71 17.61 56.65 0.044 72 7.761 56.65 0.041 73 7.7161 56.65 0.044 74 0.86 1.32 0.908 75 1.22 0.031 0.041 74 0.86 1.32 0.908 75 1.23 0.040 0.015 75 1.24 1.49 0.016 74 0.86 1.32 0.908 75 1.23 0.31 0.31 76 0.91 1.66		>7	47.78	9.85			
>7 193.51 97.52 PPBS (mg/dL) 37 17.93.6 104.40 0.000 >7 279.98 137.69 0.000 HB (g%) 37 11.34 2.43 0.301 MCV 7 82.14 5.99 0.000 MCV 7 82.14 5.99 0.000 TLC 7 7464.82 2816.11 0.077 Platelet count 57 82.45 1.10 0.224 7 2.45 1.10 0.245 0.015 7 177.61 56.65 0.041 0.015 7 177.81 249.24 0.044 0.044 HDL cholesterol-direct 57 17.10.81 289.24 0.044 HDL cholesterol-direct 57 0.31 1.66 0.041 7 0.88 1.32 0.901 0.64 0.073 8 7 0.88 1.32 0.031 0.64 0.041 0.073 0.75	FBS (mg/dL)	≤7	142.77	83.96	0.010		
PPBS (mg/dL) 57 179.36 104.40 0.000 HB (g%) 57 11.34 2.43 0.135 MCV 7 12.13 2.63 0.000 7 12.13 2.63 0.000 7 82.14 5.99 0.040 7 746.482 2816.11 0.077 7 746.482 2816.11 0.072 Platelet count 57 2.75 1.22 0.224 Total cholesterol 57 1.77 0.245 0.041 7 717.61 56.65 0.77 0.716 7 713.84 289.24 0.908 0.91 0.66 7 713.84 289.24 0.908 0.91		>7	193.51	97.52			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	PPBS (mg/dL)	≤7	179.36	104.40	0.000		
HB (g%) 57 11.34 2.43 0.135 MCV 7 12.13 2.63 MCV 7 82.14 5.99 0.040 >7 82.14 5.85 0.040 Platelet count 57 7464.82 2816.11 0.077 Platelet count 57 2.45 1.10 0.224 Platelet count 57 2.75 1.22 0.040 7 17.61 56.65 0.044 0.954 Tiglycerides 57 110.48 49.96 0.044 HDL cholesterol-direct 57 213.84 289.24 0.908 TE 7 0.56 14.72 0.908 0.914 HDL cholesterol-direct 57 0.91 1.66 0.91 0.91 TF 7 0.56 1.91 0.930 0.91 0.930 ALT 7 3.79 1.01 0.84 0.930 0.91 AST 7 3.85		>7	279.98	137.69			
>7 12.13 2.63 MCV 7 82.14 5.99 0.040 >7 82.14 5.99 0.040 >7 82.14 5.99 0.040 7 7464.82 2816.11 0.077 >7 2.45 1.10 0.224 7 2.75 1.22 0.015 7 2.75 1.22 0.015 7 17.61 56.65 0.044 7 17.761 56.65 0.044 97 213.84 289.24 0.015 7 10.18 49.96 0.044 97 0.81 43.3 0.91 10L cholesterol-direct 27 0.556 1.472 0.03 11 9.96 14.83 0.90 9.90 11 0.66 0.044 0.01 0.03 12 0.91 1.66 0.03 0.01 0.849 12 0.91 1.66 0.01	HB (g%)	≤7	11.34	2.43	0.135		
MCV 7 82.14 5.99 0.00 >7 84.64 5.85 0.077 TLC 7 7464.82 2816.11 0.077 >7 8550.22 3031.90 0.024 >7 2.75 1.22 0.015 7 149.90 50.47 0.015 7 110.48 49.96 0.044 57 213.84 298.24 0.591 7 110.48 49.96 0.041 57 12.2 0.908 0.591 7 35.56 14.72 0.91 HDL cholesterol-direct 57 0.51 1.56 7 0.91 1.66 0.93 7 3.79 1.01 0.89 10.01 57 3.85 1.91 Albumin 57 3.85 1.91 ALT 7 23.42 14.97 6GT 57 23.42 14.97 6GT 57		>7	12.13	2.63			
>7 84.64 5.85 TLC 7 7464.82 2816.11 0.077 Platelet count 57 2.45 1.10 0.224 7 2.45 1.10 0.015 7 2.75 1.22 0.015 7 149.90 50.47 0.015 7 177.61 56.65 0.044 7 213.84 289.24 0.017 HDL cholesterol-direct 57 37.19 14.83 0.591 7 35.56 14.72 0.013 0.013 7 0.88 1.32 0.003 7 0.81 1.32 0.013 7 0.84 0.94 0.013 7 3.85 1.91 0.033 84.0 0.94 0.01 0.013 97 6.84 0.94 0.010 97 3.85 1.91 0.010 97 3.79 1.01 0.033 98	MCV	7	82.14	5.99	0.040		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		>7	84.64	5.85			
>7 8550.22 3031.90 Platelet count -7 2.45 1.10 0.224 Total cholesterol -7 2.75 1.22 Triglycerides -7 117.61 56.65 Triglycerides -7 110.48 49.96 0.044 -7 213.84 289.24 0.044 -7 213.84 289.24 0.014 -7 35.56 14.72 0.91 T.B -7 0.91 1.66 0.073 -7 0.91 1.66 0.073 0.013 0.073 Albumin -7 0.88 0.94 0.93 0.93 ALT -7 3.85 1.91 0.93 0.93 ALT -7 24.39 27.94 0.93 0.93 GGT -7 3.85 1.91 0.93 0.93 0.93 GGT -7 3.84 58.68 0.93 0.93 0.93 0.93 0.93 <td< td=""><td>TLC</td><td>7</td><td>7464.82</td><td>2816.11</td><td>0.077</td></td<>	TLC	7	7464.82	2816.11	0.077		
Platelet count \$7 2.45 1.10 0.224 >7 2.75 1.22 7 Tridy cholesterol \$7 149.90 50.47 0.015 Triglycerides \$7 177.61 56.65 7 Triglycerides \$7 213.84 49.96 0.044 HDL cholesterol-direct \$7 35.56 14.72 7 T.B \$7 0.98 1.32 0.908 T. protein \$7 0.91 1.66 7 T. protein \$7 0.88 0.32 0.908 ALUT \$7 3.85 1.91 0.80 AST \$7 3.85 1.91 0.80 GGT \$7 23.42 14.97 0.303 GGT \$7 23.42 14.97 0.303 S. creatinine \$7 3.99.00 44.99 0.355 \$7 3.99.90 44.99 0.503 3.54 Cord urea \$7 <		>7	8550.22	3031.90			
>7 2.75 1.22 Total cholesterol 27 149.90 50.47 0.015 77 177.61 56.65 0.044 77 213.84 289.24 0.044 77 213.84 289.24 0.044 70 213.84 289.24 0.044 70 213.84 289.24 0.044 70 35.56 14.72 0.016 71 0.88 1.32 0.908 71 0.86 1.32 0.003 71 0.88 1.32 0.073 71 0.88 1.32 0.073 71 6.39 1.77 0.073 71 6.84 0.94 0.011 Albumin 57 3.85 1.91 0.033 71 7 3.85 1.91 0.033 6GT 7 3.814 58.68 0.033 6GT 7 3.9.90 44.99 0.551	Platelet count	≤7	2.45	1.10	0.224		
Total cholesterol \$7 149.90 50.47 0.015 >7 177.61 56.65		>7	2.75	1.22			
>7 177.61 56.65 Triglycerides 57 110.48 49.96 0.044 HDL cholesterol-direct 57 37.19 14.83 0.591 >7 35.56 14.72 0.88 1.32 0.908 T.B 7 0.91 1.66 0.073 T.protein 57 6.84 0.94 0.89 Albumin 57 3.79 1.01 0.849 ALT 7 23.94 14.31 0.930 ALT 7 23.94 14.31 0.930 ALT 7 23.42 14.97 0.01 GGT 7 3.85 1.91 0.01 Blood urea 57 23.42 14.97 0.010 57 34.33 20.43 0.010 0.010 57 42.73 30.14 0.010 0.010 6GT 57 43.33 20.43 0.030 7 3.9.90 44.99 0.563 </td <td>Total cholesterol</td> <td>≤7</td> <td>149.90</td> <td>50.47</td> <td>0.015</td>	Total cholesterol	≤7	149.90	50.47	0.015		
Triglycerides 57 110.48 49.96 0.044 >7 213.84 289.24 289.24 HDL cholesterol-direct 57 37.19 14.83 0.591 >7 35.56 14.72 0.908 0.908 T.B 7 0.88 1.32 0.908 7 0.91 1.66 0.73 0.91 0.86 7 6.84 0.94 0.84 0.94 0.93 Albumin 57 3.79 1.01 0.849 0.93 ALT 7 23.94 14.31 0.930 0.93 AST 7 38.14 58.68 0.033 0.93 0.93 6GT 57 24.39 27.94 0.93 0.9		>7	177.61	56.65			
37 213.84 289.24 HDL cholesterol-direct 37 37.19 14.83 0.591 T.B 7 35.56 14.72 0.908 T.B 7 0.88 1.32 0.908 T. protein 37 6.39 1.77 0.073 Albumin 57 6.39 1.77 0.073 ALT 7 3.85 1.91 0.849 ALT 7 23.94 14.31 0.930 ALT 7 24.39 27.94 0.355 GGT 57 24.39 27.94 0.031 GGT 57 24.39 27.94 0.355 GGT 57 23.42 14.97 0.355 GGT 57 33.42 14.99 0.355 S. creatinine 57 1.38 1.59 0.563 57 1.38 1.59 0.563 0.07	Triglycerides	≤7	110.48	49.96	0.044		
HDL cholesterol-direct \$7 37.19 14.83 0.591 >7 35.56 14.72	0,7	>7	213.84	289.24			
>7 35.56 14.72 T.B 7 0.88 1.32 0.908 >7 0.91 1.66 0 T. protein 57 6.84 0.94 Albumin 57 3.79 1.01 0.849 ALT 7 23.94 1.431 0.930 ALT 7 23.94 14.31 0.930 AST 7 38.514 58.68 0.033 GGT 7 23.42 14.97 0.14.97 GGT 7 38.14 58.68 0.033 S. creatinine 57 23.42 14.97 0.14.97 Blood urea 57 39.90 44.99 0.355 S. creatinine 57 39.90 44.99 0.355 S. creatinine 57 1.38 1.59 0.563 AST/PLT ratio 57 28.62 47.01 0.134 Tyg 51.3 0.47 0.38 0.0001 7 </td <td>HDL cholesterol-direct</td> <td>≤7</td> <td>37.19</td> <td>14.83</td> <td>0.591</td>	HDL cholesterol-direct	≤7	37.19	14.83	0.591		
T.B 7 0.88 1.32 0.908 -7 0.91 1.66		>7	35.56	14.72			
>7 0.91 1.66 T. protein \$7 6.39 1.77 0.073 Albumin \$7 6.84 0.94 0.41 Albumin \$7 3.79 1.01 0.849 ALT 7 23.94 14.31 0.930 ALT 7 23.94 14.31 0.930 AST 7 23.42 14.97 0.010 AST 7 23.42 14.97 0.010 GGT \$7 23.42 14.97 0.0563 Screatinine \$7 77.56 112.16 0.0563 Screatinine \$7 1.38 1.59 0.563 \$7 1.38 1.59 0.563 0.14 Yg \$7 1.78 3.84 0.001 \$7 1.650 35.81 0.001 0.134 Yg \$7 5.13 0.47 0.001 \$7 5.13 0.47 0.646 7	T.B	7	0.88	1.32	0.908		
T. protein 47 6.39 1.77 0.073 Albumin 57 6.84 0.94 0.849 Albumin 57 3.79 1.01 0.849 ALT 57 23.94 14.31 0.930 ALT 7 23.94 14.31 0.930 AST 7 24.39 27.94 0.013 AST 7 23.42 14.97 0.010 57 23.42 14.97 0.010 0.010 6GT 7 23.42 14.97 0.010 57 23.42 14.97 0.010 0.010 6GT 7 7.56 112.16 0.010 57 7.756 112.16 0.053 0.553 6.00 urea 57 1.38 1.59 0.563 57 1.38 1.59 0.563 0.001 57 1.650 35.81 0.001 7 7 5.13 0.47 0.368		>7	0.91	1.66			
>7 6.84 0.94 Albumin \$7 3.79 1.01 0.849 >7 3.85 1.91 0.930 ALT 7 23.94 14.31 0.930 AST 7 24.39 27.94 0.033 AST 7 23.42 14.97 0.001 GGT \$7 23.42 14.97 0.0355 Blood urea \$7 39.90 44.99 0.355 S. creatinine \$7 34.33 20.43 0.134 S. creatinine \$7 1.38 1.59 0.563 \$7 1.82 38.44 0.134 0.134 S. creatinine \$7 1.78 3.84 0.0001 \$7 1.650 35.81 0.0001 0.134 \$7 1.650 35.81 0.0001 0.0061 \$7 1.70 2.29 0.846 0.001 \$7 5.13 0.47 0.846 0.006 0.006	T. protein	≤7	6.39	1.77	0.073		
Albumin \$7 3.79 1.01 0.849 >7 3.85 1.91		>7	6.84	0.94			
>7 3.85 1.91 ALT 7 23.94 14.31 0.930 >7 24.39 27.94 0 AST 7 38.14 58.68 0.033 >7 23.42 14.97 0 0 GGT 57 23.42 14.97 0 GGT 57 24.73 30.14 0.010 >7 77.56 112.16 0 0 Blood urea 57 39.90 44.99 0.355 >7 34.33 20.43 0 0 S. creatinine 57 1.38 1.59 0.563 >7 1.88 1.59 0.563 0 Y 1.78 384 0 0 AST/PLT ratio 57 28.62 47.01 0.134 Y 16.50 35.81 0 0 Tyg 57 5.13 0.47 0 AST/PLT ratio 57 1.57	Albumin	≤7	3.79	1.01	0.849		
ALT 7 23.94 14.31 0.930 >7 24.39 27.94 1 AST 7 38.14 58.68 0.033 >7 23.42 14.97 0.010 GGT 57 42.73 30.14 0.010 >7 77.56 112.16 0.355 Blood urea 57 39.90 44.99 0.355 S. creatinine 57 1.38 1.59 0.563 >7 1.78 3.84 0.001 0.134 AST/PLT ratio 57 28.62 47.01 0.134 >7 16.50 35.81 0.001 0.001 YG 51.3 0.47 0.001 0.001 >7 5.13 0.47 0.846 0.001 >7 1.57 3.68 0.006 0.006 >7 1.57 3.68 0.006 0.006 0.006		>7	3.85	1.91			
>7 24.39 27.94 AST 7 38.14 58.68 0.033 >7 23.42 14.97 0 GGT 57 42.73 30.14 0.010 >7 77.56 112.16 0 0 Blood urea 57 39.90 44.99 0.355 >7 34.33 20.43 0 0 S. creatinine 57 1.38 1.59 0.563 >7 1.78 3.84 0 0 AST/PLT ratio 57 28.62 47.01 0.134 >7 16.50 35.81 0 0 0 Tyg 57 4.73 0.38 0.0001 0 0 >7 1.650 35.81 0 0 0 0 0 AST/ALT 57 1.70 2.29 0.846 0 0 AST/PLT ratio 57 0.56 1.06 0 0 0	ALT	7	23.94	14.31	0.930		
AST 7 38.14 58.68 0.033 >7 23.42 14.97		>7	24.39	27.94			
>7 23.42 14.97 GGT \$7 42.73 30.14 0.010 >7 77.56 112.16 0.355 Blood urea \$7 39.90 44.99 0.355 >7 34.33 20.43 0.010 S. creatinine \$7 1.38 1.59 0.563 >7 1.78 3.84 0.134 0.134 AST/PLT ratio \$7 28.62 47.01 0.134 >7 16.50 35.81 0.0001 0.134 AST/PLT ratio \$7 4.73 0.38 0.0001 >7 5.13 0.47 0.134 0.134 AST/ALT \$7 5.13 0.47 0.0001 >7 5.13 0.47 0.368 0.0001 AST/PLT ratio \$7 1.57 3.68 0.0066 >7 0.566 1.06 0.0066 0.0066	AST	7	38.14	58.68	0.033		
GGT \$7 42.73 30.14 0.010 >7 77.56 112.16 112.16 0.355 Blood urea \$7 39.90 44.99 0.355 >7 34.33 20.43 0.010 S. creatinine \$7 1.38 1.59 0.563 >7 1.78 3.84 0.134 0.134 AST/PLT ratio \$7 28.62 47.01 0.134 >7 16.50 35.81 0.0001 0.0001 7 5.13 0.47 0.346 0.0001 AST/ALT \$7 1.57 3.68 0.0001 >7 1.57 3.68 0.006 AST/PLT ratio \$7 0.22 0.20 0.006		>7	23.42	14.97			
>7 77.56 112.16 Blood urea ≤7 39.90 44.99 0.355 >7 34.33 20.43 0 S. creatinine ≤7 1.38 1.59 0.563 >7 1.78 3.84 0 0 AST/PLT ratio ≤7 28.62 47.01 0.134 >7 16.50 35.81 0 0 Tyg ≤7 4.73 0.38 0.0001 >7 5.13 0.47 0 0 AST/ALT ≤7 1.57 3.68 0 AST/PLT ratio ≤7 0.22 0.20 0.006	GGT	≤7	42.73	30.14	0.010		
Blood urea \$7 39.90 44.99 0.355 >7 34.33 20.43 0.563 S. creatinine \$7 1.38 1.59 0.563 >7 1.78 3.84 0.134 AST/PLT ratio \$7 28.62 47.01 0.134 >7 16.50 35.81 0.0001 Tyg \$7 4.73 0.38 0.0001 >7 5.13 0.47 0.846 AST/ALT \$7 1.57 3.68 AST/PLT ratio \$7 0.22 0.20 0.006 >7 0.56 1.06 0.006 0.006		>7	77.56	112.16			
>7 34.33 20.43 S. creatinine ≤7 1.38 1.59 0.563 >7 1.78 3.84 0 0.134 AST/PLT ratio ≤7 28.62 47.01 0.134 >7 16.50 35.81 0 0 Tyg ≤7 4.73 0.38 0.0001 >7 5.13 0.47 0 0.846 AST/ALT ≤7 1.57 3.68 0.006 AST/PLT ratio ≤7 0.22 0.20 0.006 >7 0.56 1.06 0.006 0.006	Blood urea	≤7	39.90	44.99	0.355		
S. creatinine ≤ 7 1.381.590.563>71.783.84AST/PLT ratio ≤ 7 28.6247.010.134>716.5035.810.000174.730.380.0001>75.130.470.846>71.573.680.006AST/PLT ratio ≤ 7 0.220.200.006		>7	34.33	20.43			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	S. creatinine	≤7	1.38	1.59	0.563		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		>7	1.78	3.84			
>7 16.50 35.81 Tyg ≤7 4.73 0.38 0.0001 >7 5.13 0.47 0.846 AST/ALT ≤7 1.70 2.29 0.846 >7 1.57 3.68 0.0001 AST/PLT ratio ≤7 0.22 0.20 0.006 >7 0.56 1.06 0.006 0.006	AST/PLT ratio	≤7	28.62	47.01	0.134		
Tyg ≤7 4.73 0.38 0.001 >7 5.13 0.47		>7	16.50	35.81			
>7 5.13 0.47 AST/ALT ≤7 1.70 2.29 0.846 >7 1.57 3.68 AST/PLT ratio ≤7 0.22 0.20 0.006 >7 0.56 1.06	Туа	≤7	4.73	0.38	0.0001		
AST/ALT ≤7 1.70 2.29 0.846 >7 1.57 3.68 AST/PLT ratio ≤7 0.22 0.20 0.006 >7 0.56 1.06		>7	5.13	0.47			
>7 1.57 3.68 AST/PLT ratio ≤7 0.22 0.20 0.006 >7 0.56 1.06 1.06	AST/ALT	≤7	1.70	2.29	0.846		
AST/PLT ratio ≤7 0.22 0.20 0.006 >7 0.56 1.06		>7	1.57	3.68			
>7 0.56 1.06	AST/PLT ratio	≤7	0.22	0.20	0.006		
		>7	0.56	1.06			

AST: Aspartate transferase, ALT: Alanine aminotransferase, PLT: Platelet, GGT: Gamma-glutamyl transferase, HDL: High-density lipoprotein, FBS: Fasting blood sugar, PPBS: Post-prandial blood sugar, TLC: Total leucocytes count, MCV: Mean corpuscular volume

Table 3: Association between gender andHbA1C						
Gender	Hb	A1C	P-value			
	≤7	>7				
Male	18 (54.5)	65 (75.6)	0.025			
Female	15 (45.5)	21 (24.4)				
Total	33 (100.0)	86 (100.0)				
In the study there is correlation between gender and HbA1C. HbA1C. Hemeglobin						

In the study there is correlation between gender and HbA1C. HbA1C: Hemoglobin A1c

significantly associated with FL disease. Early detection of FL in T2DM is important to prevent progression of the disease and minimize morbidity and mortality. An altered lipid profile level is a feature of diabetes mellitus.³⁰

Elevated levels of ALT, AST, GGT, and ALP are related to higher odds of diabetes. Also, increased serum levels of ALT, GGT, and ALP even within normal range were independently related with the increased odds

Table 4: Correlation of diabetic profile with liver function tests						
Ageabia	Duration of DM (years)	HbA1C	FBS (mg/dL)	PPBS (mg/dL)		
0.002	-0.052	-0.169	-0.127	-0.153		
0.985	0.577	0.066	0.170	0.097		
0.072	-0.008	-0.065	-0.051	-0.074		
0.433	0.928	0.484	0.584	0.424		
0.157	0.051	-0.018	-0.134	-0.091		
0.094	0.586	0.851	0.155	0.333		
-0.018	-0.119	-0.185*	-0.108	-0.120		
0.844	0.198	0.044	0.244	0.194		
	of diabetic properties Ageabia 0.002 0.985 0.072 0.433 0.157 0.094 -0.018 0.844	Of diabetic profile with liver function to Ageabia Duration of DM (years) 0.002 -0.052 0.985 0.577 0.072 -0.008 0.433 0.928 0.157 0.051 0.094 0.586 -0.018 -0.119 0.844 0.198	Ageabia Duration of DM (years) HbA1C 0.002 -0.052 -0.169 0.985 0.577 0.066 0.072 -0.008 -0.065 0.433 0.928 0.484 0.157 0.051 -0.018 0.094 0.586 0.851 -0.018 -0.119 -0.185* 0.844 0.198 0.044	of diabetic profile with liver function tests Ageabia Duration of DM (years) HbA1C FBS (mg/dL) 0.002 -0.052 -0.169 -0.127 0.985 0.577 0.066 0.170 0.072 -0.008 -0.065 -0.051 0.433 0.928 0.484 0.584 0.157 0.051 -0.018 -0.134 0.994 0.586 0.851 0.155 -0.018 -0.119 -0.185* -0.108 0.844 0.198 0.044 0.244		

AST: Aspartate transferase, ALT: Alanine aminotransferase, GGT: Gamma-glutamyl transferase, FBS: Fasting blood sugar, PPBS: Post-prandial blood sugar, PLT: Platelet

of diabetes. These results indicated the potential of elevated liver enzymes as biomarkers for the possible presence of diabetes in a study done by Noroozi Karimabad et al.³¹

In our study, when the LFT is considered there was correlation of AST and GGT which was statistically significant, with P=0.033 and 0.01. The mean and standard deviation of AST in patients with HbA1C <7 and >7 were 38.14 ± 58.68 and 23.42 ± 14.97 . Similarly for GGT with HBA1C <7 and >7 were 42.73 ± 30.14 and 77.56 ± 112.16 . However there was no statistically significant correlation was seen with ALT and total bilirubin. So, there is negative Pearson's correlation is seen among AST, GGT, and AST/PLT ratio, but not ALT with HBA1C in our study. However, statistically significant correlation was seen only with AST/PLT ratio with HbA1C (Table 4).

In a study done by Kariyawasan et al., patients with HbA1C >7 liver enzymes and lipid profile were deranged. Pearson's correlation revealed a positive co-relation between HbA1C and VLDL and a negative correlation between bilirubin and HbA1C. Positive correlation between HbA1C, ALP, TG, and VLDL indicates progression of disease and probability of cardiovascular complications. The negative correlation between HbA1C and bilirubin indicates good control and may be useful in monitoring control.³²

In our study, there was significant statistical correlation was seen with AST/PLT ratio i.e APRI score, with P=0.006. However, the Pearson's correlation revealed a negative corelation between HbA1C with APRI score.

Similarly, a study done by Alshuweishi et al., suggested that AST/PLT ratio i.e., APRI score is inexpensive, novel markers of FBG and may serve as supportive evidence in the diagnosis and management of hyperglycemic conditions. Further studies are required for using APRI score correlating with HBA1C.³³

Limitations of the study

This is a small sample study and single centre study.

CONCLUSION

Our study mainly focuses on the importance of monitoring the liver function tests in uncontrolled T2DM patients. There were several derangements in LFTs in the Type 2 diabetic patients which include AST, GGT and AST: PLT ratio. All are negatively correlated with HbA1C, but statistically significant correlation is seen only with AST: PLT ratio. Future studies are required to find out the causes of hepatic dysfunction in diabetics and to explore the impact of abnormalities of the liver on the glycemic status.

ACKNOWLEDGMENT

We thank all the patients and Department of General Medicine, ESI-PGIMSR, Medical College and Hospital, Bengaluru, Karnataka, India for the resources from provided and the logistical support that greatly facilitated the completion of this study.

REFERENCES

 Akter S, Rahman MM, Abe SK and Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: A nationwide survey. Bull World Health Organ. 2014;92(3):204-213. 213A.

https://doi.org/10.2471/BLT.13.128371

 Zheng Y, Ley SH and Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98.

https://doi.org/10.1038/nrendo.2017.151

- Home. International Diabetes Federation Home. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/factsfigures.html [Last accessed on 2000 Nov 06].
- Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance)

Asian Journal of Medical Sciences | Mar 2025 | Vol 16 | Issue 3

in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. Diabetologia. 2011;54(12):3022-3027.

https://doi.org/10.1007/s00125-011-2291-5

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, 5. Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5): 936-944.

https://doi.org/10.1111/jgh.13264

6 Belkacemi L and Belalia M. Cross-sectional pilot study about the liver enzymes profile in type 2 diabetic patients from an Algerian west region: Wilaya of Mostaganem. Diabetes Metab Syndr. 2016;10(1):S147-S150.

https://doi.org/10.1016/j.dsx.2015.10.013

7. La Vecchia C, Negri E, Decarli A and Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer. 1997;73(2):204-207.

https://doi.org/10.1002/(sici)1097-0215(19971009)73:2<204:aidijc7>3.0.co;2-#

- Levinthal GN and Tavill AS. Liver disease and diabetes mellitus. 8 Clin Diabetes. 1999;17(2):73-93.
- Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino 9. RB Jr., Kempf J, et al. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes. 2004;53(10):2623-2632.

https://doi.org/10.2337/diabetes.53.10.2623

10. Adibi A, Maleki S, Adibi P, Etminani R and Hovsepian S. Prevalence of nonalcoholic fatty liver disease and its related metabolic risk factors in Isfahan, Iran. Adv Biomed Res. 2017;6:47.

https://doi.org/10.4103/2277-9175.204590

11. Gaeini Z, Bahadoran Z, Mirmiran P and Azizi F. The association between liver function tests and some metabolic outcomes: Tehran lipid and glucose study. Hepat Monthly. 2020;20(5):e98535

https://doi.org/10.5812/hepatmon

- 12. Younossi ZM, Ong JP, Takahashi H. Global nonalcoholic steatohepatitis council. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:e1456-e1468.
- 13. Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, et al. Preparing for the NASH epidemic: A call to action. Diabetes Care. 2021;44(9):2162-2172. https://doi.org/10.2337/dci21-0020
- 14. Sunitha S, Gandham R, Wilma Delphine Silvia CR and Rao S. Evaluation of significance of liver enzymes as screening tests for the early detection of clinically asymptomatic non-alcoholic fatty liver disease in type 2 diabetes mellitus patients. Int J Biomed Adv Res. 2015;6(12):860-863.

https://doi.org/10.7439/ijbar

- 15. Philip R, Mathias M, Kumari SN, Gowda DK and Shetty JK. Evalation of relationship between markers of liver function and the onset of type 2 diabetes. Nitte Univ J Health Sci. 2014;4(2):90.
- 16. Idris AS, Mekky KF, Abdalla BE and Ali KA. Liver function tests in type 2 Sudanese diabetic patients. Int J Nutr Metab. 2011;3(2):17-21.
- 17. Shibabaw T, Dessie G, Molla MD, Zerihun MF and Ayelign B. Assessment of liver marker enzymes and its association with type 2 diabetes mellitus in Northwest Ethiopia. BMC Res Notes. 2019.12(1).707

Asian Journal of Medical Sciences | Mar 2025 | Vol 16 | Issue 3

https://doi.org/10.1186/s13104-019-4742-x

- Islam S, Rahman S, Haque T, Sumon AH, Ahmed AM and Ali N. 18 Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross-sectional study in Bangladeshi adults. Endocrinol Diabetes Metab. 2020;3(2):e00116. https://doi.org/10.1002/edm2.116
- 19. Jha SK, Yadav NK and Rizal S. Prevalence of elevated liver enzymes and its association with type 2 diabetes: A Descriptive Cross-Sectional Study among Nepalese Adults from Biratnagar, Nepal. Asian J Med Sci. 2021;12(6):50-55.
- Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, 20 Lamicchane J, et al. Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Cureus. 2018;10(11):e3626.

https://doi.org/10.7759/cureus.3626

21. Nguyen QM, Srinivasan SR, Xu JH, Chen W, Hassig S, Rice J, et al. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: The Bogalusa Heart Study. Diabetes Care. 2011;34(12):2603-2607.

https://doi.org/10.2337/dc11-0919

- Teshome G, Ambachew S, Fasil A and Abebe M. Prevalence of 22. liver function test abnormality and associated factors in type 2 diabetes mellitus: A comparative cross-sectional study. EJIFCC. 2019;30(3):303-316.
- 23. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'agostino RB Jr., and Haffner SM. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. J Diabetes. 2005;54(11):3140-3147. https://doi.org/10.2337/diabetes.54.11.3140
- 24. Alam S, Raghav A, Reyaz A, Ahsan A, Ahirwar AK, Jain V, et al. Prevalence of elevated liver enzymes and its relationship with type 2 diabetes mellitus in North Indian adults. Metabol Open. 2021;12:100130.

https://doi.org/10.1016/j.metop.2021.100130

- 25. Mathur S, Mehta DK, Kapoor S and Yadav S. Liver function in type-2 diabetes mellitus patients. Int J Sci Study. 2016;3(10):43-47. https://doi.org/10.17354/ijss/2016/09
- 26. Balogun WO, Adeleye JO, Akinlade KS, Adedapo KS and Kuti M. Frequent occurrence of high gamma-glutamyl transferase and alanine amino transferase among Nigerian patients with type 2 diabetes. Afr J Med Med Sci. 2008;37(2):177-183.
- 27. Prabhudeva N, Pasha G and Mounika K. Hepatic dysfunction in diabetes mellitus: Biochemical and ultrasonological study. J Acad Ind Res. 2014;3:164-167.
- 28. Chitkara E. Alarming high levels of transaminases in non-insulin dependent diabetes mellitus. Indian J Basic Appl Med Res. 2014;3(2):544-548.
- 29. Wan JY and Yang LZ. Liver enzymes are associated with hyperglycemia in diabetes: A three-year retrospective study. Diabetes Metab Syndr Obes. 2022;15:545-555. https://doi.org/10.2147/DMSO.S350426
- 30. Omer ZK. Effect of Elevated HbA1C on Liver and Its Function in Patients with Type II Diabetes-mellitus; 2023. Available from: https://zenodo.org/record/8001358 [Last accessed on 2023 Sep 13].
- 31. Noroozi Karimabad M, Khalili P, Ayoobi F, Esmaeili-Nadimi A, La Vecchia C and Jamali Z. Serum liver enzymes and diabetes from the Rafsanjan cohort study. BMC Endocr Disord. 2022;22(1):127. https://doi.org/10.1186/s12902-022-01042-2
- Kariyawasan CC, Balasuriya BL, Ranatunga SA, Dissanayaka 32. DM and Herath SR. Association of liver function tests, lipid profile and glycemic status in a cohort of patients with type 2.

Ann Clin Lab Sci. 2021;9(12):386. https://doi.org/10.36648/2386-5180.9.12.386

33. Alshuweishi Y, Alfaifi M, Almoghrabi Y and Alfhili MA. AST

and ALT APRI scores and dysglycemia in Saudi Arabia: A retrospective population study. Life (Basel). 2023;13(9):1881. https://doi.org/10.3390/life13091881

Authors Contribution:

Autrors Contribution: AHR- Definition of intellectual content, literature survey, prepared first draft of manuscript, implementation of study protocol, data collection, data analysis, manuscript preparation and submission of article; MTR- Concept, design, clinical protocol, manuscript preparation, editing, and manuscript revision; NKN- Design of study, statistical analysis and interpretation; AHR- Review manuscript; MTR- Review manuscript; NKN- Literature survey and preparation of figures; AAG- Coordination and manuscript revision.

Work attributed to:

Department of general medicine, ESIC Medical College, Bangaluru, Karnataka, India.

Orcid ID:

Dr. Avinash HR - ⁽⁾ https://orcid.org/0000-0001-6484-5190 Dr. Naveen K Nandeppagoudar - o https://orcid.org/0009-0003-8764-692X Mamatha TR- 0 https://orcid.org/0000-0003-2027-8141

Source of Support: Nil, Conflicts of Interest: None declared.